Topotecan
규격
123948-87-8CAS 번호
687-471-1EC 번호
(19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dioneIUPAC 명칭
C23H23N3O5화학식
421.4 g/mol분자량
topotecan; 123948-87-8; Hycamptamine; Topotecan lactone; Nogitecan; Hycamptin; Topotecane; (S)-Topotecan; Topotecanum; Topophore C; TopoCED; SKF-104864-A; 9-Dimethylaminomethyl-10-hydroxycamptothecin; NSC-641007; SKF-104864; 7M7YKX2N15; FF-10850 (liposomal topotecan); NSC609699; NSC-609699; SK&F 104864 A; SK&F-104864; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; DTXSID3042685; CHEBI:63632; NSC641007; 9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 10-((dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-, (S)-; (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-((dimethylamino)methyl)-10-hydroxy-(4S)-camptothecin; (19S)-8-((dimethylamino)methyl)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo(11.8.0.0^(2,11).0^(4,9).0^(15,20))henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (s)-10-((dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)-quinoline-3,14(4H,12H)-dione; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (S)-; RefChem:57197; DTXCID1022685; SKF104864A; SK&F104864A; SKF 104864 A; 9 Dimethylaminomethyl 10 hydroxycamptothecin; 9-((dimethylamino)methyl)-10-hydroxy-(20S)-camptothecin; NSC 609699; Topotecane [INN-French]; Topotecanum [INN-Latin]; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)-; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; CHEMBL84; Hycamtin (TN); (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione; (S)-10-((dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; Hycamtamine; Topotecan [INN:BAN]; CHEMBL1607; Topotecan (BAN); SK&F-104864-A; SK&F-S-104864A; SR-01000763672; UNII-7M7YKX2N15; CCRIS 8163; HSDB 8213; 1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE, 10-((DIMETHYLAMINO)METHYL)-4-ETHYL-4,9-DIHYDROXY-, (4S)-; SKF-S 104864; SKF 104864; TOPOTECAN [INN]; TOPOTECAN [MI]; TOPOTECAN [VANDF]; SCHEMBL3836; TOPOTECAN [WHO-DD]; NCIStruc1_001659; NCIStruc2_001796; BSPBio_002348; TOPOTECAN [EMA EPAR]; cid_60699; GTPL7101; orb1301493; SCHEMBL29350221; SCHEMBL29726458; EX-A834; HMS2090B20; HMS3715L03; BDBM50008935; BDBM50034026; EBC-07866; HSCI1_000228; MFCD00870670; s9321; AKOS015966792; CCG-221171; DB01030; FT30185; SMP2_000312; SMP2_000327; NCGC00014925-02; NCGC00014925-03; NCGC00014925-04; NCGC00014925-07; NCGC00014925-10; NCGC00014925-15; NCGC00014925-24; NCGC00178695-01; AC-11592; AC-34812; AS-75098; BP-28430; BP-29353; HY-13768; NCI60_004771; dimethylaminomethyl-ethyl-dihydroxy-[?]dione; NS00003193; T5784; D08618; EN300-117268; AB00641837-09; AB00641837-11; AB00641837-12; AB00641837-13; AB00641837-14; AB00641837_15; AB00641837_16; Q419953; SR-01000763672-3; SR-01000763672-4; BRD-K55696337-001-03-2; BRD-K55696337-003-08-7; BRD-K55696337-003-20-2; BRD-K55696337-003-21-0; BRD-K55696337-003-22-8; BRD-K55696337-003-23-6; BRD-K55696337-003-24-4; Z1501485359; Topotecan hydrochloride hydrate, >=98% (HPLC and enzymatic); 10-HYDROXY-9-((DIMETHYLAMINO)METHYL)-(20S)-CAMPTOTHECIN; (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0(2),(1)(1).0?,?.0(1)?,(2)?]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione; (20S)-10-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; (4-Ethyl-4,9-dihydroxy-3,13-dioxo-3,4,12,13-tetrahydro-1H-2-oxa-6,12a-diaza-dibenzo[b,h]fluoren-10-ylmethyl)-dimethyl-ammonium; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3'''',4'''':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; (S)-10-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; hydrochloride; (S)-11-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; (S)-11-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; hydrochloride; 10-dimethylaminomethyl-4-ethyl-4,9-dihydroxy-(4S)-3,4,12,14-tetrahydro-1H-pyrano[3'''',4'''':6,7]indolizino[1,2-b]quinoline-3,14-dione; 10-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; 10-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (Topotecan); 10-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione(Topotecan); 10-Dimethylaminomethyl-4-ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; hydrochloride; 1H-Pyrano[3',7]indolizino[1,2-b]quinoline- 3,14(4H,12H)-dione, 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-, (4S)-동의어
